EGFR amplification has been reported in up to 45% of patients with glioblastoma (The Cancer Genome Atlas Research Network 2008), and numerous studies have demonstrated the important role of the EGFR/PI3K/AKT/mTOR signaling pathway in glioblastoma progression (Lee et al. 2017, 2018; Dai et al. 2018). This evidence concerns the gene AKT1 and glioblastoma.